Skip to main content

Our strong performance in 2018 and the first quarter of 2019 has enabled us to invest in future growth through the development of our pipeline. Today, following ethics committee approval, we are initiating our first pre-eclampsia study with RUCONEST®

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline